London, UK, 7 October 2024 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce that Paolo Paoletti, MD, has joined its Board of Directors as an independent Non Executive Director (NED).
https://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svg00proteinbarhttps://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svgproteinbar2024-10-07 09:00:092024-10-07 09:00:09Myricx Bio Announces Appointment of Paolo Paoletti MD as an Independent Non Executive Director
Myricx Bio joins Kadans’ pioneering innovation centre in Canary Wharf, providing the facilities for its future expansion and pipeline progression, following a recent £90m Series A financing Kadans Science Partner (Kadans) is pleased to welcome Myricx Bio (Myricx) to its London Innovation Centre at 20 Water Street, Canary Wharf. Myricx, an innovative UK biotech company […]
https://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svg00proteinbarhttps://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svgproteinbar2024-09-12 09:00:172024-09-12 14:01:20Kadans Science Partner welcomes Myricx Bio to London Innovation Centre
London, UK, 09 July 2024 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the following board changes.
London, UK, 8 July 2024 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its series A financing raising £90m ($114m).
https://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svg00proteinbarhttps://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svgproteinbar2024-07-08 00:00:242024-07-08 11:37:27Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
London, UK, 27 November 2023 – Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase (NMT) inhibition, is pleased to announce the publication today of ground-breaking research in Nature Cell Biology1 by its collaborators at the MRC-LMS (Laboratory of Medical Sciences) that has uncovered the central role of
NMT as a druggable pathway in senescence.
https://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svg00proteinbarhttps://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svgproteinbar2023-11-27 16:07:192023-11-28 18:15:40Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies
London, UK and Shanghai, China, 21 November 2023 – Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), and WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announce […]
https://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svg00proteinbarhttps://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svgproteinbar2023-11-21 09:00:192023-11-27 16:09:24Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics
Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors. Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.
https://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svg00proteinbarhttps://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svgproteinbar2023-11-15 08:00:142023-11-15 08:02:21Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce that it has won the award for Best Poster at the 14th Annual #WorldADC conference, San Diego, California, held from October 16-19, 2023.
https://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svg00proteinbarhttps://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svgproteinbar2023-10-19 16:33:022023-11-15 08:03:41Myricx Bio Wins Best Poster at World ADC
Preclinical efficacy studies validate Myricx Bio’s proprietary N-Myristoyltransferase inhibitor (NMTi) payload platform Complete tumour regressions across a range of solid tumour xenograft models for NMTi-ADCs targeting three clinically validated tumour-associated antigens (B7-H3, TROP2 and HER2) Encouraging initial non-human primate tolerability data presented Data presentation at the 14th Annual World ADC Conference in San Diego London, […]
https://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svg00proteinbarhttps://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svgproteinbar2023-10-17 12:03:302023-11-15 08:04:06Myricx Bio to Present Preclinical Data Validating NMTi as a Novel ADC Payload Class
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs), today announces the appointment of Francesca Zammarchi Ph.D. as Chief Scientific Officer (CSO).
https://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svg00proteinbarhttps://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svgproteinbar2023-10-04 08:57:142023-10-13 16:13:52Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces the appointment of Dr. Robert McLeod as Vice President (VP) Clinical Development.
https://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svg00proteinbarhttps://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svgproteinbar2023-09-13 08:49:552023-10-13 16:13:56Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces an antibody license agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (‘Biocytogen’, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics.
https://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svg00proteinbarhttps://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svgproteinbar2023-09-07 12:02:042023-10-13 16:14:01Myricx Enters into Antibody License Agreement with Biocytogen
New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi) as a completely novel ADC payload (see poster 2635)2 New biology reveals mode of action (MoA) for NMTi via unfolded protein response (UPR) stress pathways in cancer cells (see poster 4871)3 and ability of NMTi […]
https://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svg00proteinbarhttps://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svgproteinbar2023-04-17 18:38:152023-04-18 08:11:59Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi
Rachael Brake, PhD joins the board as independent non-executive director, bringing significant drug development experience, notably from Takeda, Amgen, Millennium Co-founder Professor Ed Tate transitions from CSO to Chairman of the SAB, remaining as a board director Robin Carr, PhD steps up to CSO from his previous position as CDO Stevenage, UK, April 20 2021 […]
Start-up from Imperial College London and the Francis Crick Institute brings together 15 years of world-leading research on N-myristoyltransferase (NMT) and breakthrough discoveries related to its inhibition in cancer Initial financing of £4.5M from venture capital syndicate of experienced life sciences investors, Sofinnova Partners and Brandon Capital Partners Led by a team of world-class scientists […]
https://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svg00proteinbarhttps://myricxbio.com/wp-content/uploads/2023/10/MyricxBio_Logo_RGB_REV.svgproteinbar2019-11-16 07:49:432023-10-13 16:14:13Myricx Pharma Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer
Myricx Bio Announces Appointment of Paolo Paoletti MD as an Independent Non Executive Director
London, UK, 7 October 2024 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce that Paolo Paoletti, MD, has joined its Board of Directors as an independent Non Executive Director (NED).
Kadans Science Partner welcomes Myricx Bio to London Innovation Centre
Myricx Bio joins Kadans’ pioneering innovation centre in Canary Wharf, providing the facilities for its future expansion and pipeline progression, following a recent £90m Series A financing Kadans Science Partner (Kadans) is pleased to welcome Myricx Bio (Myricx) to its London Innovation Centre at 20 Water Street, Canary Wharf. Myricx, an innovative UK biotech company […]
Myricx Bio Announces Board Changes
London, UK, 09 July 2024 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the following board changes.
Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
London, UK, 8 July 2024 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its series A financing raising £90m ($114m).
Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies
London, UK, 27 November 2023 – Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase (NMT) inhibition, is pleased to announce the publication today of ground-breaking research in Nature Cell Biology1 by its collaborators at the MRC-LMS (Laboratory of Medical Sciences) that has uncovered the central role of
NMT as a druggable pathway in senescence.
Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics
London, UK and Shanghai, China, 21 November 2023 – Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), and WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announce […]
Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors
Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors. Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.
Myricx Bio Wins Best Poster at World ADC
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce that it has won the award for Best Poster at the 14th Annual #WorldADC conference, San Diego, California, held from October 16-19, 2023.
Myricx Bio to Present Preclinical Data Validating NMTi as a Novel ADC Payload Class
Preclinical efficacy studies validate Myricx Bio’s proprietary N-Myristoyltransferase inhibitor (NMTi) payload platform Complete tumour regressions across a range of solid tumour xenograft models for NMTi-ADCs targeting three clinically validated tumour-associated antigens (B7-H3, TROP2 and HER2) Encouraging initial non-human primate tolerability data presented Data presentation at the 14th Annual World ADC Conference in San Diego London, […]
Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs), today announces the appointment of Francesca Zammarchi Ph.D. as Chief Scientific Officer (CSO).
Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces the appointment of Dr. Robert McLeod as Vice President (VP) Clinical Development.
Myricx Enters into Antibody License Agreement with Biocytogen
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces an antibody license agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (‘Biocytogen’, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics.
Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi
New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi) as a completely novel ADC payload (see poster 2635)2 New biology reveals mode of action (MoA) for NMTi via unfolded protein response (UPR) stress pathways in cancer cells (see poster 4871)3 and ability of NMTi […]
Myricx Pharma Announces Board and Executive Appointments
Rachael Brake, PhD joins the board as independent non-executive director, bringing significant drug development experience, notably from Takeda, Amgen, Millennium Co-founder Professor Ed Tate transitions from CSO to Chairman of the SAB, remaining as a board director Robin Carr, PhD steps up to CSO from his previous position as CDO Stevenage, UK, April 20 2021 […]
Myricx Pharma Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer
Start-up from Imperial College London and the Francis Crick Institute brings together 15 years of world-leading research on N-myristoyltransferase (NMT) and breakthrough discoveries related to its inhibition in cancer Initial financing of £4.5M from venture capital syndicate of experienced life sciences investors, Sofinnova Partners and Brandon Capital Partners Led by a team of world-class scientists […]